11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
GXIRB2019-0030-1
Phase 1 mab completed
Quick answer
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) for HPV Infection is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- HPV Infection
- Phase
- Phase 1
- Modality
- mab
- Status
- completed